ID

21479

Descrizione

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT00441103

collegamento

https://clinicaltrials.gov/show/NCT00441103

Keywords

versioni (1)
  1. 24/04/17 24/04/17 -
Caricato su

24 aprile 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Multiple Sclerosis, Relapsing-Remitting NCT00441103

Inglese

Eligibility Multiple Sclerosis, Relapsing-Remitting NCT00441103

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
males and females between 18 and 60 years of age
Descrizione

Gender and age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential, as defined by either: post-menopausal or surgically sterile or use an effective method of contraception for the duration of the study
Descrizione

Gynaecological Status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0700589
have relapsing remitting multiple sclerosis (rrms) according to the revised mcdonald criteria 2005
Descrizione

Relapsing remitting multiple sclerosis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0751967
have brain and/or spinal mri with findings typical of multiple sclerosis (ms)
Descrizione

Brain and/or spinal MRI

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0412675
UMLS CUI [2]
C2454646
have disease duration for more than 12 months
Descrizione

Disease duration

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0872146
have disease activity characterized by at least one clinical event and one or more gadolinium-enhancing mri lesions within the 6 months prior to randomization
Descrizione

Clinical event or gadolinium enhancing MRI lesion

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0026769
UMLS CUI [1,2]
C0441471
UMLS CUI [2,1]
C0024485
UMLS CUI [2,2]
C0016911
have score of <=5.5 on the expanded disability status scale (edss)
Descrizione

EDSS

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0451246
be willing and able to comply with the protocol for the duration of the study
Descrizione

Compliance behaviour

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1321605
have given written informed consent prior to any study-related procedure not part of the normal medical practice
Descrizione

Informed consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
have any disease other than ms that could better explain his/her signs and symptoms
Descrizione

Differential Diagnosis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0011906
have complete transverse myelitis or bilateral optic neuritis
Descrizione

Transverse myelitis or bilateral optic neuritis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0026976
UMLS CUI [2]
C0861152
have received or have used anytime monoclonal antibodies, mitoxantrone, cytotoxic or immunosuppressive therapy (excluding systemic steroids and adrenocorticotrophic hormone [acth]), or total lymphoid irradiation
Descrizione

Monoclonal antibodies, mitoxantrone, cytotoxic or immunosuppressive therapy or total lymphoid irradiation

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0003250
UMLS CUI [2]
C0026259
UMLS CUI [3]
C0392920
UMLS CUI [4]
C0021079
UMLS CUI [5]
C1519560
have received within 3 months prior to baseline any approved disease-modifying therapy for ms, cytokine or anti-cytokine therapy, intravenous immunoglobulin, plasmapheresis, any investigational drug, or experimental procedure
Descrizione

Pharmacotherapy for MS

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013216
UMLS CUI [1,2]
C0026769
have received within 30 days prior to baseline oral or systemic corticosteroids or acth
Descrizione

Steroid therapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0149783
other protocol defined exclusion criteria could apply
Descrizione

Exclusion Criteria

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0680251
Ritorna all'inizio della pagina

Similar models

Eligibility Multiple Sclerosis, Relapsing-Remitting NCT00441103

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Gender and age
Item
males and females between 18 and 60 years of age
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Gynaecological Status
Item
female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential, as defined by either: post-menopausal or surgically sterile or use an effective method of contraception for the duration of the study
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
Relapsing remitting multiple sclerosis
Item
have relapsing remitting multiple sclerosis (rrms) according to the revised mcdonald criteria 2005
boolean
C0751967 (UMLS CUI [1])
Brain and/or spinal MRI
Item
have brain and/or spinal mri with findings typical of multiple sclerosis (ms)
boolean
C0412675 (UMLS CUI [1])
C2454646 (UMLS CUI [2])
Disease duration
Item
have disease duration for more than 12 months
boolean
C0872146 (UMLS CUI [1])
Clinical event or gadolinium enhancing MRI lesion
Item
have disease activity characterized by at least one clinical event and one or more gadolinium-enhancing mri lesions within the 6 months prior to randomization
boolean
C0026769 (UMLS CUI [1,1])
C0441471 (UMLS CUI [1,2])
C0024485 (UMLS CUI [2,1])
C0016911 (UMLS CUI [2,2])
EDSS
Item
have score of <=5.5 on the expanded disability status scale (edss)
boolean
C0451246 (UMLS CUI [1])
Compliance behaviour
Item
be willing and able to comply with the protocol for the duration of the study
boolean
C1321605 (UMLS CUI [1])
Informed consent
Item
have given written informed consent prior to any study-related procedure not part of the normal medical practice
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Differential Diagnosis
Item
have any disease other than ms that could better explain his/her signs and symptoms
boolean
C0011906 (UMLS CUI [1])
Transverse myelitis or bilateral optic neuritis
Item
have complete transverse myelitis or bilateral optic neuritis
boolean
C0026976 (UMLS CUI [1])
C0861152 (UMLS CUI [2])
Monoclonal antibodies, mitoxantrone, cytotoxic or immunosuppressive therapy or total lymphoid irradiation
Item
have received or have used anytime monoclonal antibodies, mitoxantrone, cytotoxic or immunosuppressive therapy (excluding systemic steroids and adrenocorticotrophic hormone [acth]), or total lymphoid irradiation
boolean
C0003250 (UMLS CUI [1])
C0026259 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C0021079 (UMLS CUI [4])
C1519560 (UMLS CUI [5])
Pharmacotherapy for MS
Item
have received within 3 months prior to baseline any approved disease-modifying therapy for ms, cytokine or anti-cytokine therapy, intravenous immunoglobulin, plasmapheresis, any investigational drug, or experimental procedure
boolean
C0013216 (UMLS CUI [1,1])
C0026769 (UMLS CUI [1,2])
Steroid therapy
Item
have received within 30 days prior to baseline oral or systemic corticosteroids or acth
boolean
C0149783 (UMLS CUI [1])
Exclusion Criteria
Item
other protocol defined exclusion criteria could apply
boolean
C0680251 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial